Status:
COMPLETED
Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management
Lead Sponsor:
University Hospital, Toulouse
Conditions:
COVID-19
Eligibility:
All Genders
18-110 years
Brief Summary
Persons infected with Severe Acute Respiratory Syndrome (SARS) SARS-CoV-2 vary in severity from being asymptomatic to having fever, cough, sore throat, general weakness and fatigue and muscular pain a...
Detailed Description
The primary objective of IMMUNOMARK-COV is to define an applicable immune signature predicting clinical worsening on COVID-19 patient admission in order to help physicians to take informed therapeutic...
Eligibility Criteria
Inclusion
- For COVID-19 hospitalized patients
- Polymerase chain reaction (PCR) proven SARS-CoV-2 infection
- Participation to Toulouse clinical cohort
- Having signed consent for inclusion in the Toulouse biobanks For COVID-19 healthcare workers attending dedicated clinics
- PCR proven SARS-CoV-2 infection
- Having signed consent for inclusion in the Toulouse biobanks
Exclusion
- Pregnancy or breastfeeding
- Participation in another interventional clinical study involving exploratory treatment or blood sampling.
Key Trial Info
Start Date :
May 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 2 2023
Estimated Enrollment :
304 Patients enrolled
Trial Details
Trial ID
NCT04668170
Start Date
May 5 2020
End Date
May 2 2023
Last Update
December 11 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Bordeaux
Bordeau, France, 33000
2
University Hospital Toulouse
Toulouse, France, 31059